Fig. 2
From: A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
Inhibition of NAK pathway by baricitinib. Baricitinib includes inhibition of viral receptor-mediated endocytosis, which involves the NF-κB activating kinase (NAK) family